Gainers

• Liminatus Pharma (NASDAQ:LIMN) stock rose 24.1% to $0.23 during Wednesday's after-market session. The company's market cap stands at $8.5 million.
• BiomX (AMEX:PHGE) stock increased by 12.33% to $0.67. The company's market cap stands at $3.7 million.
• Jupiter Neurosciences (NASDAQ:JUNS) shares moved upwards by 12.19% to $0.23. The market value of their outstanding shares is at $11.6 million. The company's, Q1 earnings came out 4 days ago.
• Stablecoin Development (AMEX:SDEV) shares moved upwards by 11.18% to $1.69. The market value of their outstanding shares is at $41.2 million. The company's, Q1 earnings came out 3 days ago.
• ALPS Group (NASDAQ:ALPS) stock increased by 9.36% to $0.75. The market value of their outstanding shares is at $128.7 million.
• Longeveron (NASDAQ:LGVN) stock moved upwards by 8.28% to $0.77. The market value of their outstanding shares is at $20.9 million.

Losers

• HCW Biologics (NASDAQ:HCWB) shares declined by 15.6% to $2.05 during Wednesday's after-market session. The company's market cap stands at $7.1 million. The company's, Q1 earnings came out 4 days ago.
• MetaVia (NASDAQ:MTVA) shares fell 9.0% to $2.63. The company's market cap stands at $9.7 million. The company's, Q1 earnings came out 4 days ago.
• INVO Fertility (NASDAQ:IVF) shares decreased by 7.74% to $1.55. The market value of their outstanding shares is at $21.6 million.
• Gelteq (NASDAQ:GELS) shares declined by 7.72% to $0.42. The company's market cap stands at $4.1 million.
• Silexion Therapeutics (NASDAQ:SLXN) shares declined by 7.42% to $0.49. The market value of their outstanding shares is at $1.0 million. The company's, Q1 earnings came out 3 days ago.
• Nanobiotix (NASDAQ:NBTX) shares declined by 7.0% to $40.14. The market value of their outstanding shares is at $2.2 billion. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.